Canadian medical technology company Kent Imaging has partnered with US-based wound healing research firm SerenaGroup to enhance wound tissue analysis by using near infrared imaging technology on its non-invasive KD203 device.

Kent’s hand-held, portable device is a tissue oxygenation measurement system designed to assess oxygen saturation (StO2), relative oxyhemoglobin (HbO2) and deoxyhemoglobin (Hb) levels in superficial tissue.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all
“As part of the collaboration, SerenaGroup will use Kent’s technology as the standard of care for the assessment of wound oxygenation.”

The imaging technology delivers 2D colour-coded images that offer the information necessary for clinicians to identify at-risk tissue.

These insights can also help in treatment decisions and optimise patient outcomes in wound care, plastic surgery and other reconstructive applications.

As part of the collaboration, SerenaGroup will use Kent’s technology as the standard of care for the assessment of wound oxygenation.

The technology will be integrated into the SerenaGroup facilities and used in future clinical and preclinical research.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

SerenaGroup founder and medical director Dr Serena said: “One of the most troublesome and elusive criteria in treating wounds is the timely and accurate assessment of viable tissue.

“Kent’s device will propel us a long way down the healing path with a technology that has been lacking across the board in the Wound Care space.”

To date, SerenaGroup is said to have conducted more than 100 wound healing clinic trials.

Kent Imaging CEO Pierre Lemire said: “Our joint belief is that we can improve patient care and outcomes by significantly improving clinically relevant data that is required to assess and manage wounds.”